Proptosis

Both teprotumumab and tocilizumab reduce inflammation and thyroid eye disease severity, including among adults who were nonresponders to steroid treatment, according to findings published in Thyroid.

The FDA approved expanded indication language to allow the use of teprotumumab for the treatment of thyroid eye disease for any level of activity or duration, according to a press release.

Teprotumumab is associated with a greater reduction in proptosis than placebo at 24 weeks among adults with chronic thyroid eye disease and a low clinical activity score, according to topline results.

A 59-year-old man was transferred from an outside hospital to the University of New Mexico Hospital for acute left eye vision loss and proptosis.

Less than 5% of adults with thyroid eye disease who completed a full course of teprotumumab therapy required an additional course of the agent, according to a presenter at the American Thyroid Association annual meeting.

CHICAGO — Patients who received Tepezza to treat thyroid eye disease showed improved extraocular muscle size that correlated to improved diplopia and motility, according to a presenter here.

CHICAGO — Pretreatment evaluation of fat-to-muscle ratio in thyroid eye disease will allow for the best treatment choice, a presenter here said.

CHICAGO — Since its approval in 2020, Tepezza has become a go-to treatment for moderate to severe thyroid eye disease, unseating orbital decompression as the most used treatment, according to a presenter here.

A 41-year-old woman was referred to the neuro-ophthalmology service at the New England Eye Center for left-sided proptosis, left upper lid edema and progressively worsening vision in the left eye for about 5 months.

IV methylprednisolone was linked to a small change in proptosis from baseline compared with placebo in patients with thyroid eye disease, while teprotumumab may improve proptosis and diplopia vs. IV methylprednisolone.